NCCN Receives $2 Million in Research Funding from Boehringer Ingelheim to Study Nintedanib* in Colorectal and Lung Cancers
Newswise,
The NCCN Oncology Research Program (ORP) received a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to…